Navigation Links
MAP Pharmaceuticals to Present Data From LEVADEX® Pharmacokinetics and Pharmacodynamics Safety Studies at the 63rd Annual Meeting of the American Academy of Neurology
Date:4/12/2011

c. to co-promote LEVADEX to neurologists and pain specialists in the U.S. MAP Pharmaceuticals also applies its proprietary drug particle and inhalation technologies to generate new pipeline opportunities by enhancing the therapeutic benefits of proven drugs, while minimizing risk by capitalizing on their known safety, efficacy and commercialization history.  Additional information about MAP Pharmaceuticals can be found at http://www.mappharma.com

Forward-Looking Statements In addition to statements of historical facts or statements of current conditions, this press release contains forward-looking statements, including with respect to MAP Pharmaceuticals' LEVADEX product candidate.  Actual results may differ materially from current expectations based on risks and uncertainties affecting the company's business, including, without limitation, risks and uncertainties relating to the preparation and filing of a New Drug Application and the regulatory process to have the company's LEVADEX product candidate approved for commercial use.  The reader is cautioned not to unduly rely on the forward-looking statements contained in this press release.  MAP Pharmaceuticals expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.  Additional information on potential factors that could affect MAP Pharmaceuticals' results and other risks and uncertainties are detailed in its Annual Report on Form 10-K for the year ended December 31, 2010, available at http://edgar.sec.gov. CONTACT:Nicole Foderaro

Lisa BorlandWCG

MAP Pharmaceuticals, Inc.(415) 946-1058

650-386-3122nfoderaro@wcgworld.com
'/>"/>

SOURCE MAP Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... , Indien, July 23, 2014 /PRNewswire/ ... additional scope für Arbeiten für Sadara Chemical ... comprehensive Engineering Information System innerhalb des integrierten ... Dieser award of additional scope im Wert ... des zuvor abgeschlossenen Vertrags dar, dessen Wert ...
(Date:7/22/2014)... July 23, 2014   - Investment ... Pharmaceutical Co., Ltd. (hereinafter "Taiho"), a fully-fledged oncology pharmaceutical ... be investing US$30 million in Remiges BioPharma Fund (hereinafter ... Taiho has a long history of developing ... and cancer patients. Our development of TAS-102 is an ...
(Date:7/22/2014)... , July 22, 2014  Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2014 on Thursday, July 31, ... Robin , president and chief executive officer, will host a ... Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... conference call can be accessed through a link that is ...
Breaking Medicine Technology:Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 2Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 4Taiho Pharmaceutical Invests US$30 Million in Remiges BioPharma Fund, LP 2Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets 3
... Healthcare announced today that it has acquired Alpha Care ... health economics and policy solutions for pharmaceutical, medical device, ... will expand its health economics, pricing and market access ... office in Berlin, Germany, will allow Boston Healthcare to ...
... being released by the U.S. Food and Drug Administration: ... Fast Facts FDA ... to feed SimplyThick, a thickening agent for management of ... The product may cause necrotizing enterocolitis (NEC), a life-threatening ...
Cached Medicine Technology:Boston Healthcare Acquires Alpha Care GmbH, Expanding Health Economics, Pricing and Reimbursement Consulting Presence in Europe 2FDA: Do Not Feed SimplyThick to Premature Infants 2FDA: Do Not Feed SimplyThick to Premature Infants 3
(Date:7/23/2014)... 23, 2014 PartnerTech Inc. , ... Lawrenceville, Georgia, welcomed Andreas von Uexkull to their facilities, ... the U.S. von Uexkull, a top trade official from ... of the U.S. to bring awareness and insight to ... Investment Partnership (TTIP). , As an expert on ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Previously, the crew ... pencil and a spreadsheet. Now, the department’s 53 ... Scheduling and Workforce Management system. , “Scheduling our personnel with ... It was hard to keep track of when people could ... this time to this time, and we would have to ...
(Date:7/23/2014)... Controlling pain during childbirth and post delivery may reduce ... a Northwestern Medicine perinatal psychiatrist, in a July 23 ... Wisner,s editorial is based on a new Chinese study ... anesthesia during a vaginal delivery had a much lower ... the epidural. , "Maximizing pain control in labor and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Print ... Print Audit Facilities Manager web portal. Facilities Manager ... releases of the software as well as numerous ... , Print Audit Facilities Manager is a powerful, ... to remotely collect meter reads, automate supplies fulfillment ...
(Date:7/22/2014)... Recently, iFitDress.com, a popular supplier of wedding dresses and ... of white party dresses to its product category. ... now available on its website. As a special offer, all ... can get a discounted rate, up to 54% off. , ... customers, so its marketing specialist believes the new white party ...
Breaking Medicine News(10 mins):Health News:Swedish Official Tours PartnerTech’s U.S. Facility 2Health News:Swedish Official Tours PartnerTech’s U.S. Facility 3Health News:This Fire Department Allows Personnel to Schedule Themselves - Saving Administration Up To 60 Hours a Month 2Health News:This Fire Department Allows Personnel to Schedule Themselves - Saving Administration Up To 60 Hours a Month 3Health News:Controlling childbirth pain tied to lower depression risk 2Health News:Print Audit® Releases Facilities Manager 3.1.0R 2Health News:Elegant White Party Dresses Now Provided by Distinguished Company iFitDress.com 2
... , SCOTTSDALE, Ariz., July 15 ... Healthcare Trust of America, Inc.) (the "REIT"), a self-managed non-traded ... and sale agreement (the "Agreement") to acquire a 16 building ... Carolina. The transaction involves approximately 855,000 square feet of medical ...
... , , CARY, ... CRTX ), a specialty pharmaceutical company focused on ... respiratory and related markets, today announced that it has ... Drug Administration (FDA) for an extended-release antitussive product (CRTX ...
... , , , ... on the data presented today, the U.S. Food and Drug Administration (FDA) ... HCI liposome injection) and docetaxel did not provide ... or metastatic breast cancer. , , Women ...
... , WESTBROOK, Maine, July 15 IDEXX Laboratories, ... 2009 second quarter financial results for Friday, July 24, at approximately 7:00 ... 9:00 a.m. (eastern) on that day. , , ... through a link on the IDEXX Web site, www.idexx.com. An archived edition ...
... , , , ... AHS ), the leading healthcare staffing company in the United States, ... Financial Officer (CFO), effective August 10, 2009. Bailey brings nearly 30 ... insurance and pharmaceutical industries. , , Mr. ...
... method still shows promise, scientists say , WEDNESDAY, ... hopes for a minimally invasive cancer-screening technique known ... to be less effective than standard colonoscopy at ... Belgium suggests. , Although able to identify many ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6Health News:AMN Healthcare Names New Chief Financial Officer 2Health News:AMN Healthcare Names New Chief Financial Officer 3Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 2Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 3
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Vertical punch designed to create a 1.5mm clean cylindrical hole. Rotatable for convenient positioning. Flat Handle. Overall length 87mm....
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Medicine Products: